GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
GRAIL, Inc. director Gregory L. Summe acquired 237 deferred stock units on October 15, 2026, in lieu of $32,136.99 in cash fees payable for his director service. The units were granted under the company’s deferred stock program and 2024 Equity Incentive Plan, based on a price of $135.46 per share, the closing price that day, and vest immediately upon grant. His reported direct holdings following the transaction were 45,909 shares.
GRAIL, Inc. director William J. Chase was granted 153 deferred stock units on October 15, 2026, in lieu of $20,794.52 in cash fees payable for his director service. The units were valued at $135.46 per share, the closing price of GRAIL common stock that day. The awards will vest immediately upon grant date. His reported direct position following the transaction was 43,131 shares.
GRAIL, Inc. Chief Executive Officer Joshua J. Ofman reported selling 20,000 shares of common stock on October 15, 2026. The sales were made under a Rule 10b5-1 trading plan adopted on December 2, 2025.
The six reported tranches were 400 shares at a weighted-average $133.1175 per share, 1,000 at $134.3843, 3,400 at $135.4435, 7,052 at $136.8329, 6,034 at $137.6310, and 2,114 at $138.7864. Each price is a weighted average for shares sold in multiple transactions.
GRAIL, Inc. director Steven Mizell received a grant of 148 deferred stock units on October 15, 2026, in lieu of cash fees payable for his director service. The award was based on a common-stock closing price of $135.46 per share and vested immediately upon grant. Mizell’s reported direct holdings after the transaction were 42,978 shares of common stock.
GRAIL, Inc. (GRAL) reports a proposed sale by Joshua Ofman, identified as a director and officer, of 5,000 common shares, with an aggregate market value of $698,500 and an approximate sale date of October 15, 2026. The shares are identified as restricted stock units acquired from the issuer on August 18, 2024. Ofman’s reported sales during the prior three months include 61,452 shares for $6,006,378 on September 21, 2026, and 5,000 shares for $425,098 on August 27, 2026; both are labeled 10b5-1 sales.
GRAIL, Inc. Chief Growth Officer Andrew John Partridge reported a sale of 7,873 shares on October 5, 2026, at a weighted average price of $146.39 per share. An executing broker made the sales automatically as sell-to-cover transactions for withholding taxes upon award vesting and share delivery. The shares were sold in a block trade involving multiple transactions. Partridge directly held 155,865 shares after the transaction.
GRAIL, Inc. Chief Financial Officer Aaron Freidin reported selling 23,619 common shares on October 5, 2026, at a broker-calculated weighted-average price of $146.39 per share. An executing broker automatically sold the shares to cover withholding taxes upon award vesting and share delivery, in multiple transactions as part of a block trade. Freidin directly held 225,364 shares after the transaction. No Rule 10b5-1 plan is reported.
GRAIL, Inc. (GRAL) reports a Rule 144 notice covering the sale of 7,873 common shares by Andrew Partridge, an Officer, with an aggregate market value of $1,152,533.19 and an approximate sale date of October 5, 2026. ETRADE Financial Corporation is listed as broker and NASDAQ as the exchange. The remarks say the shares were sold to cover tax withholding obligations arising from restricted stock unit vesting on October 3, 2026. Donald Lang signed as attorney-in-fact for Andrew Partridge.
GRAIL, Inc. officer Aaron Freidin reported a proposed sale of 23,619 common shares, with an aggregate market value of $3,457,599.58; the approximate sale date is October 5, 2026. The notice lists 45,840 common shares acquired on October 3, 2026, through vesting of restricted stock units awarded under GRAIL's equity incentive plans. Its remarks state that the sale represents shares sold to cover tax withholding obligations arising from that vesting. It also lists Aaron Freidin's sales of 7,900 common shares for $671,579 on August 27, 2026, and 4,100 shares for $382,679.13 on September 21, 2026.
GRAIL, Inc. Chief Financial Officer Aaron Freidin sold 4,100 shares of common stock on September 21, 2026, across three transactions: 1,779 shares at a weighted average of $92.2631 per share, 1,800 at $93.9156, and 521 at $95.0000. The first weighted-average price reflects sales from $92.19 to $93.00 inclusive; the second reflects sales from $93.89 to $94.33 inclusive. The sales were made under a Rule 10b5-1 trading plan adopted December 11, 2025.